Press releases.
Press releases
Press releases
Immutep Quarterly Activities Report Q3 FY25
April 29th 2025
Immutep to Participate in Upcoming Investor Conferences
April 2nd 2025
Immutep Quarterly Activities Report Q2 FY25
January 31st 2025
Patient Enrolment Completed for EFTISARC-NEO Phase II Trial
January 22nd 2025
Patient Enrolment Completed for INSIGHT-003
January 6th 2025
Immutep Quarterly Activities Report Q1 FY25
October 29th 2024
Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit
October 10th 2024
Immutep Receives A$3.6 million R&D Tax Incentive from French Government
September 24th 2024
Immutep to Participate in Upcoming Investor Conferences
August 7th 2024
Immutep Quarterly Activities Report Q4 FY24
July 31st 2024
Immutep Quarterly Activities Report Q3 FY24
April 29th 2024
Immutep Quarterly Activities Report Q2 FY24
January 30th 2024
Immutep Receives A$2.6 million R&D Tax Incentive from French Government
December 7th 2023
Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial
November 22nd 2023
Immutep to Participate in November Investor Events
November 2nd 2023
Immutep Quarterly Activities Report Q1 FY24
October 31st 2023
Immutep Receives ~A$1.13 Million R&D Tax Incentive
October 25th 2023
Immutep Announces Publication of Abstracts at ESMO Congress 2023
October 16th 2023
Immutep to Participate in September Investor Conferences
September 5th 2023
Immutep Quarterly Activities Report Q4 FY23
July 31st 2023
Immutep Completes A$80 Million Capital Raise
June 27th 2023
Immutep Quarterly Activities Report
April 27th 2023
Immutep Appoints Dr. Florian Vogl as Chief Medical Officer
April 26th 2023
Immutep Announces Changes to the Board
April 11th 2023
Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC
February 6th 2023
Immutep Quarterly Activities Report
January 30th 2023
Immutep Receives Australian R&D Tax Incentive
November 14th 2022
Immutep to Participate in Two Upcoming Investor Conferences
November 2nd 2022
Immutep Quarterly Activities Report
October 25th 2022
Immutep to Participate in Two Upcoming Investor Conferences
September 26th 2022
Immutep Receives A$2.7 million R&D Tax Incentive from French Government
September 23rd 2022
Immutep Appoints LAG-3 Pioneer, Dr Frédéric Triebel to Board
September 13th 2022
Immutep Quarterly Activities Report
July 28th 2022
Immutep Quarterly Activities Report
April 29th 2022
Immutep Appoints Lucy Turnbull as Non-Executive Director
February 25th 2022
Immutep to Present at Healthcare Investor Conferences
February 24th 2022
Immutep to Present at February Investor Conferences
January 31st 2022
Immutep Quarterly Activities Report
January 25th 2022
Immutep Advances IMP761 Manufacturing
December 16th 2021
Immutep Quarterly Activities Report
October 28th 2021
Immutep to present Phase II TACTI-002 data at SITC 2021
October 1st 2021
Immutep Receives A$3.4 million R&D Tax Incentive from French Government
September 29th 2021
Immutep to Present at Healthcare Investor Conferences
September 28th 2021
Immutep’s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline
August 31st 2021
Immutep Quarterly Activities Report
July 13th 2021
Immutep Reveals a New anti-LAG-3 Research Program
June 8th 2021
Immutep Operational Update
May 7th 2021
Immutep Quarterly Activities Report
April 19th 2021
Immutep Receives A$1,155,055 R&D Tax Incentive
April 16th 2021
Immutep Expands Part B of TACTI-002 Study
March 5th 2021
Immutep Quarterly Activities Report
January 21st 2021
Ulcerative Colitis Phase II Study of GSK2831781 Discontinued
January 21st 2021
Immutep Upscales Efti Manufacturing
December 16th 2020
Immutep Operational Update
December 15th 2020
Immutep Announces Expansion of TACTI-002 Collaboration Trial
November 18th 2020
Immutep Announces Australian Patent Grant for IMP701 Antibody
November 9th 2020
Immutep’s Phase II TACTI-002 Study Reports Encouraging Data at SITC
November 9th 2020
Immutep Granted European Patent for IMP761
October 21st 2020
Immutep Activities Report for the First Quarter of Fiscal Year 2021
October 21st 2020
Immutep Announces Improving Results from Stage I of Phase II TACTI-002 Study
September 17th 2020
Immutep Reports Improving Results from INSIGHT-004 Trial
September 17th 2020
New Data From Immutep’s Efti To Be Presented At ESMO
August 26th 2020
Immutep Issues Newsletter Update to Shareholders
August 17th 2020
Immutep Quarterly Activities Report
July 23rd 2020
Immutep Receives A$1,437,826 R&D Tax Incentive
June 22nd 2020
Immutep Reports First Results from INSIGHT-004 Study
May 31st 2020
Immutep Reports Positive Phase II TACTI-002 Data
April 28th 2020
Enrollment completed for the INSIGHT-004 Study
April 21st 2020
Immutep Quarterly Activities Report
April 20th 2020
Immutep Advances Cell Line Development for IMP761
April 15th 2020
Immutep Receives Second IND Approval for Efti from US FDA
March 9th 2020
Immutep Reports Positive TACTI-002 Data
February 19th 2020
Immutep to Present TACTI-002 Interim Data at German Cancer Congress
February 4th 2020
Immutep Activities Report
January 29th 2020
Immutep Expands Part C of TACTI-002 Due to Positive Data
January 9th 2020
INSIGHT-004 Clinical Trial Update
December 19th 2019
Immutep Announces European Patent Grant for LAG525 Antibody
November 14th 2019
Operational Update
October 28th 2019
Immutep Announces Data Presentations at Upcoming Industry Conferences
October 10th 2019
Immutep Receives A$2.5 Million R&D Tax Incentive from French Government
October 10th 2019
Immutep to Receive £4M Milestone Payment from GSK
September 23rd 2019
Immutep Announces Japanese Patent Grant for LAG525 Antibody
September 17th 2019
Immutep Granted European Patent for Eftilagimod Alpha in Cancer
August 22nd 2019
Immutep Completes A$6M Entitlement Offer
August 6th 2019
Operational Update
July 26th 2019
Immutep to Host Key Opinion Leader Call
June 24th 2019
Immutep Presentation at ASCO 2019
June 3rd 2019
Operational Update
April 30th 2019
Immutep to Present IMP761 Preclinical Results in Global Webcast
March 18th 2019
Immutep doses First Patient in TACTI-002 Phase II Trial
March 6th 2019
Immutep to Present at Upcoming Industry Conferences
February 26th 2019
Operational Update
November 1st 2018
Immutep Announces Data Presentations at Upcoming Industry Conferences
October 24th 2018
Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference
September 26th 2018
Progress Towards Clinical Development of IMP761 - A LAG-3 Agonist Antibody
September 3rd 2018
TACTI-mel Patient Recruitment Complete and Operational Update
August 7th 2018
Immutep to Present at 2018 ASCO Annual Meeting
May 4th 2018
Operational Update
April 2nd 2018
Immutep Commences Patient Dosing In Additional TACTI-mel Cohort
March 21st 2018
Immutep Raises A$6.85M Through Institutional Placement
March 11th 2018
Immutep receives A$686,704 R&D Tax Incentive
March 4th 2018
Operational Update
December 12th 2017
Prima BioMed Becomes Immutep
November 29th 2017
Prima Secures European Patent Grant for Lead Product IMP321 in Cancer
November 21st 2017
Prima BioMed Changes its Name to Immutep Ltd
November 20th 2017
Eftilagimod Alpha (LAG-3Ig or IMP321) Pre-IND Meeting with the FDA
November 15th 2017
Dr. Frédéric Triebel Presented at the World Immunotherapy Congress 2017
October 31st 2017
Dr. Frédéric Triebel presenting at the World Immunotherapy Congress 2017
October 19th 2017
Prima Secures Japanese Patent Grant for IMP731 Antibody
September 8th 2017
Prima BioMed Appoints Non-Executive Director to the Board
August 20th 2017
Financial Update 2H17
July 19th 2017
Operational Update
June 26th 2017
ASCO Poster 2017
June 6th 2017
USA Patent Grants for IMP321 in Cancer
March 2nd 2017
First Half 2017 Operational Update
February 25th 2017
Prima BioMed Receives ~A$860,000 Tax Credit Payment from French Government
February 14th 2017
Prima BioMed to Present at 2nd Annual Cancer Immunotherapy Conference
January 24th 2017
Prima BioMed to Maintain NASDAQ Listing
January 19th 2017
Prima BioMed Commences Recruitment for Second Cohort of Melanoma Trial
January 13th 2017
Prima BioMed enters new Material Transfer Agreement with Cytlimic
January 6th 2017
PRIMA TO PRESENT AT 2016 SOCIETY FOR IMMUNOTHERAPY OF CANCER CONFERENCE
October 13th 2016
Operational Update
August 18th 2016
PRIMA BIOMED RECEIVES NASDAQ NOTICE OF BID PRICE DEFICIENCY
August 10th 2016
PRIMA BIOMED TO MAINTAIN NASDAQ LISTING
July 6th 2016
PRIMA BIOMED RECEIVES NASDAQ NOTICE OF BID PRICE DEFICIENCY
March 4th 2016
JAPANESE PATENT GRANTS FOR IMP321 IN CANCER
February 5th 2016
US PATENT GRANTS FOR IMP731 ANTIBODY
January 28th 2016
PRIMA BIOMED INITIATES PHASE I MELANOMA STUDY IN AUSTRALIA
January 27th 2016
PRIMA BIOMED INITIATES PHASE IIB STUDY IN METASTATIC BREAST CANCER
December 22nd 2015
PRIMA BIOMED PROGRESSES JAPANESE COLLABORATION
December 11th 2015
PRIMA BIOMED RECEIVES TAX REBATE FROM AUSTRALIAN GOVERNMENT
November 26th 2015
PRIMA BIOMED RECEIVES GRANT FROM THE SAXONY DEVELOPMENT BANK
October 9th 2015
September 25th 2015
PRIMA BIOMED ANNOUNCES COMMENCEMENT OF MILESTONES FOR IMP701 PROGRAM
August 14th 2015
Re: Results of 2015 Extraordinary General Meeting
August 1st 2015
Prima Biomed Ltd 2015 Extraordinary General Meeting
July 31st 2015
PRIMA BIOMED RAISES A$10M THROUGH SHARE PURCHASE PLAN
July 24th 2015
SHARE PURCHASE PLAN OFFER DOCUMENTS
July 10th 2015
A MESSAGE FROM THE CHAIRMAN
June 29th 2015
PRIMA BIOMED TO MAINTAIN NASDAQ LISTING
June 4th 2015
PRIMA BIOMED ANNOUNCES JAPANESE COLLABORATION
May 11th 2015
PRIMA BIOMED PRIORITISING IMP321
February 27th 2015
FINANCIAL MILESTONE PAYMENT TO BE RECEIVED FROM GSK
January 27th 2015
$777K R&D TAX INCENTIVE REFUND RECEIVED
January 20th 2015
PRIMA BIOMED APPOINTS GLOBAL HEAD OF INVESTOR RELATIONS
January 20th 2015